View the public protocol
Merck Sharp & Dohme LLC, Harvard Pilgrim Health Care Institute, Reagan-Udall Foundation for FDA, CVS Health, Carelon Research, Humana HealthCare Research, Health Partners Institute, Marshfield Clinic Health System, Vanderbilt University Medical Center, Meyers Primary Care Institute, Optum Epidemiology. Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycemic agents (MK-8835-062) (EUPAS31718; Study ID 50276; MK-8835-062). Amsterdam: European Medicines Agency (EMA); 2019 Oct 17. Available from: https://catalogues.ema.europa.eu/node/3540/administrative-details
